# Genomic epidemiology reveals geographical clustering of multidrug-resistant *Escherichia coli* sequence type (ST)131 associated with bacteraemia in Wales, United Kingdom

# 4 1.1 Author names

Bull<sup>3,4</sup> https://orcid.org/0000-0001-6620-758X, 5 Rhvs Τ. White<sup>1,2</sup> Matthew J. https://orcid.org/0000-0002-8701-0417, Clare R. Barker<sup>3</sup> http://orcid.org/0000-0002-3276-6 5628, Julie M. Arnott<sup>5</sup>, Mandy Wootton<sup>4</sup> https://orcid.org/0000-0002-2227-3355, Lim S. 7 Jones<sup>4</sup>, Robin A. Howe<sup>4</sup>, Mari Morgan<sup>5</sup>, Melinda M. Ashcroft<sup>6</sup> https://orcid.org/0000-0001-8 9157-4533, Brian M. Forde<sup>7</sup> https://orcid.org/0000-0002-2264-4785, Thomas R. Connor<sup>3\*</sup> 9 https://orcid.org/0000-0003-2394-6504, Scott A. Beatson<sup>1,2\*</sup> https://orcid.org/0000-0002-10 11 1806-3283

12

# 13 **1.2** Affiliation

- 14 <sup>1</sup>School of Chemistry and Molecular Biosciences and Australian Infectious Disease Research
- 15 Centre, The University of Queensland, Brisbane, Queensland 4072, Australia
- <sup>2</sup>Australian Centre for Ecogenomics, The University of Queensland, Brisbane, Queensland
   4072, Australia
- <sup>3</sup>Microbiomes, Microbes and Informatics Group, Organisms and Environment Division,
   School of Biosciences, Cardiff University, Cardiff, Wales CF10 3AX, United Kingdom
- <sup>4</sup>Public Health Wales Microbiology, University Hospital Wales, Cardiff, Wales CF14 4XW,
- 21 United Kingdom
- 22 <sup>5</sup>Healthcare Associated Infection, Antimicrobial Resistance & Prescribing Programme
- (HARP), Public Health Wales, 2 Capital Quarter, Tyndall Street, Cardiff, Wales CF10 4BZ,
   United Kingdom
- <sup>6</sup>Department of Microbiology and Immunology, The University of Melbourne at The Peter
- 26 Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
- 27 <sup>7</sup>The University of Queensland, UQ Centre for Clinical Research (UQCCR) and Australian
- 28 Infectious Disease Research Centre, Royal Brisbane & Women's Hospital Campus, Herston,
- 29 Queensland 4029, Australia
- 30

# 31 1.3 Corresponding authors

- 32 Thomas R. Connor;
- **33** Telephone: +44-29-20874147;
- 34 Email: connortr@cardiff.ac.uk
- 35
- 36 Scott A. Beatson;
- **37** Telephone: +61-7-33654863;
- 38 Email: s.beatson@uq.edu.au
- 39

# 40 1.4 Keywords

- 41 Escherichia coli; bacteraemia; ST131; whole-genome sequencing; genomics
- 42

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 43 1.5 Author notes

All supporting data, code and protocols have been provided within the article or through
supplementary data files. Supplementary methods and supplementary tables are available with
the online version of this article.

47

#### 48 **1.6** Abbreviations

3GCs, third-generation cephalosporins; AMR, antimicrobial resistance; BWA, Burrows-49 50 Wheeler Aligner; CA, common ancestor; *catB*, chloramphenicol-related O-acetyltransferase; CDS, coding sequence; CI, confidence interval; contigs, contiguous sequences; ECB, 51 *Escherichia coli* bacteraemia; ESBLs, extended-spectrum  $\beta$ -lactamases; *febE*, ferric 52 enterobactin transport protein; fryC, fructose-like permease IIC component; fumC, fumarate 53 hvdratase class II; GATK, Genome Analysis Tool Kit; HPD, highest posterior density; 54 55 INDELS, insertions and deletions; IQR, interquartile range; IS, insertion sequences; MCC, maximum clade credibility; MCMC, Markov chain Monte Carlo; *mdh*, malate dehydrogenase; 56 57 ML, maximum likelihood; MLST, multilocus sequence typing; NCBI, National Center for 58 Biotechnology Information; NHS, National Health Service; NICE, National Institute for Clinical Excellence; PHW, Public Health Wales; RefSeq, Reference Sequence; SNPs, single-59 nucleotide polymorphisms; SACU, Specialist Antimicrobial Chemotherapy Unit; SRA, 60 Sequence Read Archive; ST, sequence type; syn, synonymous; UK, United Kingdom; UPEC, 61 Uropathogenic Escherichia coli; USA, United States of America; UTIs, urinary tract 62 63 infections; WGS, whole-genome sequencing; XAT, xenobiotic acyltransferase.

64

# 65 **2.** Abstract

Increasing resistance to third-generation cephalosporins (3GCs) threatens public health, 66 67 as these antimicrobials are prescribed as empirical therapies for systemic infections caused by Gram-negative bacteria. Resistance to 3GCs in urinary tract infections (UTIs) and bacteraemia 68 69 is associated with the globally disseminated, multidrug-resistant, uropathogenic Escherichia 70 coli sequence type (ST)131. This study combines the epidemiology of E.coli blood culture surveillance with whole-genome sequencing (WGS) to investigate ST131 associated with 71 bacteraemia in Wales between 2013 and 2014. This population-based prospective genomic 72 73 analysis investigated temporal, geographic, and genomic risk factors. To identify spatial 74 clusters and lineage diversity, we contextualised 142 genomes collected from twenty hospitals, 75 against a global ST131 population (n=181). All three major ST131 clades are represented across Wales, with clade C/H30 predominant (n=102/142, 71.8%). Consistent with global 76 77 findings, Welsh strains of clade C/H30 contain  $\beta$ -lactamase genes from the bla<sub>CTX-M-1</sub> group (n=65/102, 63.7%), which confers resistance to 3GCs. In Wales, the majority of clade C/H30 78 strains belonged to sub-clade C2/H30Rx (n=88/151, 58.3%), whereas sub-clade C1/H30R 79 strains were less common (n=14/67, 20.9%). A sub-lineage unique to Wales was identified 80 81 within the C2/H30Rx sub-clade (named GB-WLS.C2/H30Rx) and is defined by six non-

recombinogenic single-nucleotide polymorphisms (SNPs), including a missense variant in *febE* 82 83 (ferric enterobactin transport protein) and fryC (fructose-like permease IIC component), and the loss of the capsular biosynthesis genes encoding the K5 antigen. Bayesian analysis 84 predicted that GB-WLS.C2/H30Rx diverged from a common ancestor (CA) most closely 85 related to a Canadian strain between 1998 and 1999. Further, our analysis suggests a 86 87 descendent of GB-WLS.C2/H30Rx arrived through an introduction to North Wales circa 2002, 88 spread and persists in the geographic region, causing a cluster of cases (CA emerged circa 2009) with a maximum pair-wise distance of 30 non-recombinogenic SNPs. This limited 89 90 genomic diversity likely depicts local transmission within the community in North Wales. This 91 investigation emphasises the value of genomic epidemiology, allowing detection of suspected 92 transmission clusters and the spread of genetically similar/identical strains in local areas. These 93 analyses will enable targeted and timely public health interventions.

94

# 95 **3. Impact statement**

96 Uropathogenic Escherichia coli (UPEC) is a leading cause of bacteraemia, resulting in substantial mortality and morbidity, with rates of E. coli bacteraemia (ECB) becoming a 97 98 particular concern in Wales(1). Previous genomic and multilocus sequence typing (MLST) 99 studies have identified that ECB cases are disproportionately caused by specific groups [sequence types (ST)] of related E. coli. Previous work reports ST131 as a globally 100 101 disseminated lineage associated with bacteraemia and antimicrobial resistance (AMR). Despite 102 widespread study of ECB, the temporal and geographic patterns of key ECB clones remain an 103 important area of study. Moreover, by gaining a detailed understanding of the population structure of key ECB clones, it should be possible to develop and improve public health 104 105 measures to reduce the risk of ECB and act to combat the rise of AMR. Using whole-genome 106 sequencing, we describe the temporal and spatial relationship of a collection of E. coli ST131 bacteraemia cases sampled across Wales. High-resolution analyses of genetic variants 107 108 identified a local (North Wales) cluster of strains within the highly antimicrobial-resistant sub-109 clade C2/H30Rx, which are characterised by resistance to nitrofurantoin and the loss of the K5 capsule. Notably, AMR stewardship guidelines in Wales recently changed to include 110 111 nitrofurantoin as a first-line treatment for uncomplicated UTIs. This local cluster likely 112 represents environmentally-mediated community transmission, environmentally mediated, 113 from the strain's common ancestor that existed circa 2009, highlighting the need for national

114 genomic surveillance, close to real-time, to track and understand the evolution of AMR in 115 communities.

116

#### **117 4. Data summary**

The study sequences are available in the National Center for Biotechnology Information 118 (NCBI) under BioProject accession number PRJNA729115. Raw Illumina sequence read data 119 NCBI 120 have been deposited to the sequence read archive [SRA (https://www.ncbi.nlm.nih.gov/sra)] under the accession numbers SRR14519411 to 121 SRR14519567. A complete list of SRA accession numbers is available in Table S1 (available 122 in the online version of this article). The high-quality draft assemblies have been deposited to 123 GenBank under the accession numbers JAHBGJ000000000 to JAHBMG000000000, and 124 JAHBRR000000000 to JAHBRT000000000. The programs used to analyse raw sequence 125 reads for polymorphism discovery and whole-genome sequencing based phylogenetic 126 reconstruction are available as described in the materials and methods. The authors confirm all 127 128 supporting data, code, and protocols have been provided within the article or through 129 supplementary data files.

130

# 131 **5. Introduction**

132 Uropathogenic Escherichia coli (UPEC), bacteria causing infection rather than commensal bacteria, are the leading cause of urinary and systemic infections. UPEC present an increasing 133 burden to public health due to increasing antimicrobial resistance (AMR). Increasing rates of 134 135 AMR can lead to treatment failures and progression to systemic bacteraemia infections. Additionally, the emergence and dissemination of UPEC strains encoding AMR are causing 136 economic damage to countries and healthcare systems(2). Incidences of E. coli associated 137 bacteraemia are increasing globally. In Wales, the 5-year rolling average age-standardised 138 139 mortality for deaths involving E. coli bacteraemia (ECB) almost doubled from 4.0 [95% confidence interval (CI): 2.3 to 6.4] per 1 million population in 2002-06, to 7.7 (95% CI: 5.4 140 141 to 10.6) in 2006-10 (Figure S1)(1). Previous studies have shown that most urinary tract infections (UTIs) are caused by a limited number of key UPEC clonal lineages including 142 143 sequence types (ST)131, ST69, ST73, ST95 and ST12(3-5). UPEC are predominantly found 144 within the E. coli phylogenetic groups B1, B2, or D.

E. coli ST131 is a high-risk pandemic clone that is frequently associated with bacteraemia(6) 146 147 and UTIs, and is a major circulating lineage in the United Kingdom (UK)(7). The successful 148 transmission of ST131 globally is attributed to: (i) resistance to many treatments by the carriage 149 of genes encoding resistance to multiple antimicrobial agents(8-10); (ii) the ability to cause 150 disease that other opportunistic or commensal strains do not possess through pathogenicity, 151 fitness, and metabolic factors(11-13); (iii) the ability to survive in human serum(14) due to 152 capsule production(15); and (iv) transmission in various environments including healthcareand community-acquired transmission(16). ST131 can colonise and persist in hosts for 153 154 extended periods causing recurrent UTIs, typically within 1-year of the initial infection(17). 155 ST131 cases frequently harbour resistance to many broad-spectrum therapies such as third-156 generation cephalosporins (3GCs)(18, 19) and fluoroquinolones(20). In ST131, the carriage of 157 extended-spectrum  $\beta$ -lactamases (ESBLs) facilitates the principal resistance mechanism to 3GCs. 158

159

In 2018, the UK National Institute for Clinical Excellence (NICE) issued guidelines concerning 160 161 acute pyelonephritis(21). This recommended urine culture susceptibility testing and promoted 162 the use of several  $\beta$ -lactams, trimethoprim, ciprofloxacin (fluoroquinolone), or amoxicillin and 163 clavulanic acid as first-line antibiotics. This could be contributing to increasing rates of ESBLproducing E. coli across the UK(22). Between 2017-2018, data from England and Wales 164 showed that at least 14.1% (n=4,950/35,050)(23) and 13.3% (n=354/2,663)(24) of E. coli 165 bloodstream isolates presented resistance to 3GCs, respectively. In England, this translates to 166 167 approximately 5,000 annual cases, often due to ST131(4, 7). Resistance to  $\beta$ -lactams like 3GCs can lead to increased usage of last-line therapies like carbapenems, with carbapenem resistance 168 169 in UPEC also associated with ST131(25, 26). In 2017, rates of resistance to fluoroquinolones in ECB cases across Wales were as at least 20.3% (n=540/2,663)(24). NICE also promotes the 170 171 use of nitrofurantoin or trimethoprim (first-line), and pivmecillinam or fosfomycin (secondline) antibiotics against lower UTIs(27). However, trimethoprim is no longer recommended in 172 173 Wales for the treatment of UTIs in the 65 and over age group(24). The increase in antimicrobial-resistant infections is problematic on several levels. For example, patients are 174 175 more likely to receive inappropriate empirical therapy involving an agent to which the pathogen 176 is resistant. The circulation of strains with extensive levels of resistance to key antimicrobials, such as 3GCs, increases the likelihood of UTI treatment failures, prolonging the length of 177 infection, potentially allowing the bacteria to flourish by removing commensal bacteria which 178

179 compete for bacterial growth, and increases severe outcomes such as the risk of a patient180 developing bacteraemia, resulting in increased morbidity and mortality.

181

182 Genomic epidemiology, the use of whole-genome sequencing (WGS) in epidemiological 183 investigations, is increasing worldwide in public health responses. With increasing rates of 184 antimicrobial-resistant ECB, it is vital to understand the genetic relatedness of circulating 185 strains on a local, national, and global scale. This work investigated the evolution of ST131 strains from patients in Wales with bacteraemia identified over a 12-month period. Genomic 186 187 sequence data enabled the characterisation of circulating ST131 in Wales, showing multiple 188 introductions of this global clone with localised or national transmission. Our analyses also 189 reveal multiple bacteraemia cases caused by a unique geographically-restricted, monophyletic 190 subgroup of ST131 within North Wales characterised by ESBL-production.

191

#### 192 **6.** Methods

#### 193 6.1 Welsh E. coli isolate collection and genome sequencing

Public Health Wales (PHW) laboratories were asked to submit all E. coli blood isolates 194 195 from blood samples collected between April 2013 and March 2014, to the national Specialist Antimicrobial Chemotherapy Unit (SACU) at University Hospital Wales. The isolate dataset 196 197 was linked to routine microbiological surveillance data by PHW to obtain isolate AMR profiles. Novel AMR profiles and profiles with phylo-geography were characterised by 198 199 polymerase chain reaction. Selected samples were sequenced based on their determined phylogenetic groups. Isolates were transported to Cardiff University, cultured overnight in 200 liquid culture, and extracted using a Promega (Wisconsin, USA) Maxwell instrument. Samples 201 202 were sequenced as paired-end reads on either the NextSeq 500 or HiSeq 2500 platform at 203 (Illumina Inc, San Diego, CA, USA) the Oxford Genomics Centre 204 (https://www.well.ox.ac.uk/ogc/) or MicrobesNG (https://microbesng.com/). DNA libraries were prepared using a mixture of the Nextera XT® Library Preparation Kit and the NEBNext® 205 206 Ultra<sup>™</sup> Library Preparation Kit (Illumina Inc, San Diego, CA, USA), following the 207 manufacturer's instructions in both cases.

208

This genomic surveillance of ECB in Wales collected 157 non-duplicate clinical *E. coli* ST131
strains as part of routine microbiological surveillance data from hospitals across six
administrative units known as health boards (Figure S2). Patient anonymity was maintained by

pseudonymised data that went outside PHW. Epidemiological information, including isolate 212 213 names and available metadata are summarised in Supplementary Tables S1 and S2. The WGS of the 157 E. coli isolates generated a median of 0.89 million paired-end reads per sample 214 [interquartile range (IQR): 0.43 to 1.09 million; range: 0.14 to 3.37 million] (Table S2). 215 Sequence read data for all Welsh isolates were submitted to the National Center for 216 217 Biotechnology Information Sequence Read Archive under BioProject accession number PRJNA729115. The methods used for quality control for this dataset are available in the 218 Supplementary Methods. Briefly, we identified and excluded the sequence data for 15 219 220 isolates from further analysis based on the sequencing coverage below 20-fold (Table S3).

221

# 222 6.2 Draft genome assembly

Quality-trimmed paired-end reads for the remaining 142 Welsh strains were de novo 223 224 assembled using MGAP (https://github.com/dsarov/MGAP---Microbial-Genome-Assembler-225 Pipeline), which implements: Velvet v1.2.10(28); VelvetOptimiser 226 (https://github.com/tseemann/VelvetOptimiser); GapFiller v1.10(29); ABACAS v1.3.1(30) [scaffolds against the chromosome of *E. coli* ST131 strain EC958 (GenBank: HG941718)]; 227 228 IMAGE v2.4(31); SSPACE v2.0(32); Pilon v1.22(33); and MIRA v4(34). Contigs from the draft assemblies were ordered against the complete chromosome of EC958 using Mauve 229 230 version snapshot 2015-02-25(35). QUAST v4.5(36) assessed the assembly statistics generated from MGAP by comparing each isolate to EC958 (Table S4). 231

232

#### 233 6.3 Complementary datasets

234 To facilitate the geographic analysis of the 142 Welsh ST131 isolates within the global context, available isolate datasets were downloaded including: (i) sequence read data from the 235 NCBI sequence read archive (SRA); (ii) draft assemblies; and (iii) associated metadata from 236 Ben Zakour et al.(10) (n=189) and Kidsley et al.(37) (n=19). Notably, six draft assemblies 237 from the Ben Zakour et al. study were replaced with the complete chromosomes: CD306 238 239 (GenBank: CP013831); JJ1886 (GenBank: CP006784); JJ1887 (GenBank: CP014316); JJ2434 (GenBank: CP013835); S65EC (GenBank: CP036245); and ZH193 (GenBank: CP014497) 240 (Table S5). The methods used for *in silico* gene typing and generation of an assembly based 241 ST131 phylogeny (initial context) for this global dataset are available in the Supplementary 242 243 Methods.

#### 245 6.4 Compiling a high-quality ST131 clade C/H30 global dataset

246 For context, the Welsh clade C/H30 strains (n=102) were inputted against a global 247 collection of clade C/H30 ST131 strains (n=117) from three published studies(9, 10, 38) as 248 featured in Kidsley et al.(37). Several complete genomes were integrated by simulating error 249 free reads using ART (version ART-MountRainier-2016-06-05)(39) to 60x coverage with an 250 insert size of  $340 \pm 40$  bp. These included known clade C/H30 ST131 genomes: 2/0 (GenBank: 251 CP023853); 4/0 (GenBank: CP023849); 4/4 (GenBank: CP023826); 4/1-1 (GenBank: CP023844); MNCRE44 (GenBank: CP010876); U12A (GenBank: CP035476); U13A 252 (GenBank: CP035477); U14A (GenBank: CP035516); U15A (GenBank: CP035720); and 253 uk P46212 (GenBank: CP013658). For this investigation, clade C/H30 strains JJ2183 (SRA: 254 SRS456889), MVAST0036 (SRA: SRS456851), MVAST046 (SRA: SRS456881), and 255 256 MVAST077 (SRA: SRS456882) were removed from the dataset based on the average 257 sequence coverage depth below 20-fold.

258

#### 259 6.5 Identifying genetic variants

260 High-resolution analyses of genetic variants was performed using the Burrows-Wheeler Aligner v0.7.15(40); SAMtools v1.2(41); Picard v2.7.1 261 (https://github.com/broadinstitute/picard); the Genome Analysis Tool Kit v3.2-2 (GATK)(42, 262 43); BEDTools v2.18.2(44); and SNPEff v4.1(45) as implemented in SPANDx v3.2(46). In 263 264 brief, the trimmed reads were mapped to the complete chromosome of EC958; which was isolated in March 2005 in the United Kingdom from a community-onset urine infection in an 8-265 266 year-old girl(11). When analysing the Illumina reads, 20 clade C/H30 genomes from Price et 267 al.(38) were excluded from this example dataset due to erroneous Phred quality encoding (Table S6). Our final dataset consisted of 226 genomes representing previously published 268 269 datasets (n=124, including 16 complete genomes) and our Welsh collection (n=102) (Table 270 S7).

271

#### 272 6.6 High-resolution phylogeny of the clade C/H30 ST131 sub-lineage

The 226 strains [EC958 reference (n=1) and dataset (n=225)] were assessed for the presence of strain mixtures (see Supplementary Methods). Briefly, this approach readily flagged seven strains as a probable mixture based on the high number of ambiguous singlenucleotide polymorphisms (SNPs) (from a total of 7,592 SNPs) compared with the remaining 219 genomes [Median 51 (0.7%); IQR 28 to 102 (0.4 to 1.3%); range 2 to 171 (0.0 to 2.3%)].

The quality-trimmed paired-end Illumina reads from the remaining 218 high-quality clade 278 C/H30 isolates were mapped onto the chromosome of EC958 using SPANDx with default 279 280 parameters to generate annotated SNP/INDEL matrices. To account for recombination, regions of high-density clustered SNPs (≥3 SNPs found within a 100 bp window) were 281 282 removed. Sites were excluded if a SNP was called in regions with less than half or greater 283 than 3-fold the average genome coverage on a genome-by-genome basis. SPANDx generated an alignment of 4,354 non-recombinant, orthologous, biallelic core-genome SNPs 284 from the 219 strains. Lastly, a maximum likelihood (ML) phylogenetic tree from the non-285 286 recombinant SNP alignment was generated using RAxML v8.2.10(47) (GTR-GAMMA 287 correction) thorough optimisation of 20 distinct, randomized maximum parsimony trees, before 288 adding 1,000 bootstrap replicates. The resulting phylogenetic tree was visualised using FigTree 289 v1.4.4 (http://tree.bio.ed.ac.uk/software/figtree/) and EvolView v2(48, 49).

290

#### 291 6.7 Root-to-tip regression analysis

292 A regression analysis was used to estimate the temporal signal in the clade C/H30 ST131 sub-lineage between the root-to-tip genetic distance using TempEst v1.5.15(50). The ML 293 294 phylogenetic tree that was reconstructed from the alignment of 4,354 non-recombinant, orthologous, biallelic core-genome SNPs (as described above) was used as the input into 295 296 TempEST. Four problematic sequences that did not match the evolutionary trajectory of the remaining strains within the lineage were identified and were removed from the temporal 297 analysis [BA1581 (SRA: SRR14519500), JJ2643 (SRA: SRS456891), S77EC (SRA: 298 ERR161304), and U004 (SRA: SRS456902)]. SPANDx was rerun using the same parameters 299 300 as described above, only with the '-s' flag set to none to move straight to the comparative genomics and error correction section of the pipeline. The new alignment for Bayesian 301 302 phylogenetic inference consisted of 4,150 non-recombinant, orthologous, biallelic coregenome SNPs from 215 clade C/H30 ST131 strains. The ML rebuilt using the methods above. 303 304 Again, the tree was rooted by CD306.

305

#### **306 6.8 Bayesian temporal analysis**

To further the temporal analysis, a time calibrated phylogenetic tree was generated with
BEAST2 v2.6.1(51). The alignment of 4,150 SNPs was run through jModelTest v2.1.10(52,
53), which identified the GTR nucleotide substitution model as the best-fit evolutionary model.
To test if the strict clock or uncorrelated relaxed clock best-fit our dataset, initial models were

created using tip dates, a GTR substitution model, and a coalescent prior with a constant 311 population. Both models were tested with the Nested sampling Bayesian computation 312 313 algorithm v1.1.0 within the BEAST2 package with a particle count of 1, sub chain length of 5,000, and Epsilon of  $1.0 \times 10^{-6}$ . This analysis provides evidence in favour of the uncorrelated 314 relaxed clock model. Various population models were compared to ensure selection of the best-315 fit model. These included the Bayesian skyline, coalescent constant, and exponential growth 316 population size change models. The Gamma Site Model Category Count was set to four and 317 the GTR substitution model rates determined from jModelTest were included (i.e., rate AC = 318 0.94, AG = 3.16, AT = 1.10, CG = 0.14, CT = 3.12, and GT = 1.00). Notably, the initial clock 319 320 rate was set to  $7.61 \times 10^{-4}$  (as estimated from the root-to-tip regression analysis in TempEST) with a uniform distribution and an upper bound of 0.1. All other priors were left as default. A 321 322 total of three independent Markov chain Monte Carlo (MCMC) generations for each analysis were conducted for 100 million generations. Trees were sampled every 1,000 generations 323 324 which resulted in triplicate samples of 100,000 trees for each model test. All BEAST runs were imported into Tracer v1.7.1 (http://github.com/beast-dev/tracer/) to assess statistics. 325 LogCombiner v2.5.0 (BEAST 2 package) then combined the replicated analyses for each 326 model with a 10% burn-in to assess convergence/appropriate sampled run. Finally, 327 TreeAnnotator v2.4.5 (BEAST 2 package) removed the 10% burn-in and generated maximum 328 329 clade credibility (MCC) trees for each run (established from 243 million trees), reporting 330 median values with a posterior probability limit set at 0.5. FigTree was used to visualise the 331 annotated MCC trees. We determined the best-fitting tree model as the uncorrelated relaxed exponential clock model with the Bayesian skyline population size change model based on the 332 333 mean tree likelihood scores (Table S8).

# 335 **7. Results**

#### 336 7.1 E. coli ST131 strains from Wales

Previous genomic and multilocus sequence typing (MLST) investigations identified that 337 ECB cases were disproportionately caused by E. coli ST131 (n=187/720, 26.0%)(54). This 338 study involved E. coli ST131 isolates cultivated from blood specimens collected from twenty 339 340 hospitals across six health boards within Wales (Figure S2). Of the 157 isolates collected over the study (between 2013 and 2014), 142 passed quality-control on the sequence data [females 341 n=70/142 (49.3%), males n=69/142 (48.6%), no sex recorded n=3/142 (2.1%)]. Patients were 342 typically older, with a median age of 80 years (IQR: 70 to 87 years; range: 19 to 105 years), 343 344 which reflects the known patient profile of ECB cases(1).

345

#### 346 7.2 Major ST131 clades are represented amongst ST131 circulating Wales

347 The 142 draft genomes had a median total length of 5.20 Mb (IQR: 5.10 to 5.27; range: 4.75 to 5.48 Mb), a median GC content of 50.7% (IQR: 50.7 to 50.8%; range: 50.5 to 51.3%), 348 349 and a median N50 statistic of 199.59 kb (IQR: 102.39 to 245.60 kb; range: 6.42 to 499.50 kb). 350 All 142 genomes are ST131, except for BA1243 and BA1279 (same Clonal Complex) that 351 differ in the fumarate hydratase class II (fumC) and malate dehydrogenase (mdh) genes 352 respectively (Figure S3). The Welsh ST131 draft genomes have a high prevalence of chromosomal mutations conferring high level resistance (MICs >32mg/L) to fluoroquinolones, 353 where most (n=102/142, 71.8%) contain double variants in gyrA (D87N and S83L) and parC 354 (E84V & S80I). An additional ten genomes contain a single variant in gyrA (S83L) which 355 356 usually confers low level resistance (MICs 0.5mg/L). The *bla*<sub>CTX-M-15</sub> gene (CTX-M-1 group) is the most common (n=65/142, 45.8%) AMR gene encoding ESBLs. The *bla*<sub>OXA-1</sub> gene is also 357 358 common (n=62/142, 43.7%) amongst Welsh strains, which encodes resistance to amoxicillin/clavulanic acid, and piperacillin/tazobactam (antibiotic/\beta-lactamase inhibitor when 359 360 in combination with ESBL genes). Notably, 36.6% (n=52/142) of the strains carry both  $bla_{CTX}$ -361 M-15 and  $bla_{OXA-1}$ . To capture a snapshot of the genomic diversity and population structure 362 amongst ST131 strains circulating in Wales, the draft assemblies of the 142 genomes were contextualised with a global collection of ST131 cases sequenced elsewhere (n=208) (Figure 363 364 S4). The 13,758 non-recombinant core-genome SNP alignment represents a core-genome alignment of 2,575,140 bp relative to the 5,109,767 bp reference chromosome EC958. All three 365 well-supported major ST131 clades (A, B, and C) are represented across Wales. While most 366

isolates are located within clade C/H30 (n=103/142, 72.5%), representatives from clade A 367 (n=22/142, 15.5%) and clade B (n=17/142, 12.0%) are present at similar frequencies. 368

- 369
- 370

#### 7.3 The majority of clade C/H30 ST131 isolates circulating Wales are ESBL-producing, 371 conferring resistance to 3GCs

To infer the phylogenetic relatedness of isolates and determine AMR gene carriage, we 372 373 created a core-genome SNP alignment of clade C/H30 strains only using SPANDx. This alignment of global clade C/H30 strains (n=219) comprises 4,354 non-recombinant 374 375 orthologous biallelic SNPs representing a  $\sim$ 4,005,300 bp core-genome (regions estimated to the nearest 100 bp with  $\geq$ 95% coverage across all genomes) relative to the 5,109,767 bp 376 chromosome of EC958. Almost half (n=102/219, 46.6%) of our global clade C/H30 lineage 377 comprised isolates collected from bacteraemia cases across Wales (Figure 1; see branch lengths 378 379 expressed as SNPs in Figure S5). In our combined dataset, the majority of clade C/H30 ST131 strains belonged to sub-clade C2/H30Rx (n=151/219, 68.9%), with sub-clade C1/H30R 380 381 (n=67/219, 30.6%) less common. Sub-clade C2/H30Rx mostly comprised Welsh strains 382 (n=88/151, 58.3%), whereas in sub-clade C1/H30R, the Welsh strains comprise only 20.9% of 383 the sub-lineage (n=14/67). The majority (n=68/102, 66.7%) of these clade C/H30 isolates demonstrate an ESBL-producing genotype. In terms of acquired resistance to  $\beta$ -lactams, CTX-384 M-type metallo- $\beta$ -lactamase genes were dominant, with the most prevalent being the 385  $bla_{\text{CTX-M-1}}$  group (n=65/102, 63.7%). The second most prevalent  $\beta$ -lactamase (n=61/102, 386 59.8%) bla<sub>OXA-1</sub>, which encodes resistance to amoxicillin/clavulanic acid, 387 and piperacillin/tazobactam (antibiotic/ $\beta$ -lactamase inhibitor). 388



392 (ST)131 isolates plotted against  $\beta$ -lactam resistance complement. Phylogeny inferred from 393 4,354 non-recombinant orthologous biallelic core-genome single-nucleotide polymorphisms 394 (SNPs) from 219 strains. Moderate recombination SNP density filtering in SPANDx (excluded 395 regions with  $\geq$ 3 SNPs in a 100 bp window). SNPs are derived from read mapping to the 396 reference chromosome EC958 (GenBank HG941718). Phylogenetic trees are rooted according 397 to the CD306 (GenBank: CP013831) outgroup. Branch lengths represent nucleotide

substitutions per site as indicated by the scale bar. Bootstrapping using 1,000 replicatesdemonstrates the robustness of the branches.

400

# 401 7.4 The GB-WLS.C2/H30Rx Welsh cluster shares a common ancestor of North 402 American origin

403 Among the C2/H30Rx population (Figure 1), there is a cluster of 35 isolates from Wales 404 that are separated by a maximum pair-wise distance of 123 non-recombinogenic SNPs between 405 strains BA264 (collected in South Wales in 2013) and BA2000 (collected in North Wales in 406 2014). Strains within this C2/H30Rx Welsh cluster (designated GB-WLS.C2/H30Rx) are 407 closely related with a median pair-wise distance of 48 (IQR: 21 to 92) non-recombinogenic SNPs. The GB-WLS.C2/H30Rx sub-lineage has descended from a common ancestor (CA) 408 shared with the clinical O25b:H4:K5 strain S125EC (SRA: ERS126605), which was cultivated 409 in 2002 from a patient with a surgical wound in Canada(9), pointing towards the global 410 411 dispersion of ST131. Isolates within GB-WLS.C2/H30Rx are distinguishable by six unique core-genome SNPs relative to EC958, two of which are in genes associated with fitness or 412 413 virulence (cusB; cation efflux system mediating resistance to copper and silver and fepE; ferric 414 enterobactin siderophore transport protein) (Table 1). Outside of the core-genome, strains 415 within GB-WLS.C2/H30Rx (except for BA876) have lost region II of the K5 capsule loci, likely because of recombination, resulting in a loss of the K5 capsule production (Figure 2). In 416 E. coli, group 2 capsular polysaccharides typically share conserved regions in the capsule loci 417 (regions I and III). These conserved regions encode the transmembrane complex involved in 418 419 the export and assembly of the capsular polysaccharides (15, 55, 56). Region II is, however, 420 serotype-specific and encodes for enzymes responsible for synthesizing the capsular polysaccharide. Strains within GB-WLS.C2/H30Rx have region II of the capsule locus 421 422 replaced with two genes, the *catB* chloramphenicol-related O-acetyltransferase (xenobiotic acyltransferase [XAT]), conferring resistance to chloramphenicol and a HAD-IA family 423 hydrolase, which has been resolved with the completion of the clinical strain O25:H4 collected 424 in Saudi Arabia in 2014 (GenBank: CP015085). In the C2/H30Rx strain O25:H4, the low 425 426 average guanine-cytosine content (42.18%) of the 15.2 kb capsule locus suggests a foreign origin. 427

Position in EC958	EC958	Cluster	Change <sup>b</sup>	Impact	Codon	Gene	Product
604.042			<u></u>		202		
601,912	C	1	Syn	LOW	383	CUSB	Cation efflux system protein
632,160	с	Т	Q=>stop	HIGH	130	fepE	Ferric enterobactin transport
1,672,896	т	С	Syn	LOW	130	dosP	Oxygen sensor protein
2,698,528	G	Α	T=>I	MODERATE	232	fryC	Fructose-like permease IIC component
2,902,622	т	С					
2,964,604	Α	G	Syn	LOW	165	pncC	Nicotinamide-nucleotide amidohydrolase

# Table 1. Specific variants between *Escherichia coli* strain EC958 and GB-WLS.C2/H30Rx

Emboldened and italicised nucleotides are specific to sub-clade C2/H30Rx EC958 and isolates within the Welsh cluster, respectively <sup>b</sup> Consequence of SNP relative to EC958 (C2/H30Rx). Synonymous change (Syn); non-synonymous changes to protein-coding genes are shown by single letter amino acid abbreviation (EC958 sequence on left, SNP impact on right); blank lines indicate variant in intergenic region

429

430



Figure 2. Major structural features and nucleotide pair-wise comparisons of the group 2
capsules in *Escherichia coli*. Nucleotide comparisons between the sub-clade C1/H30R
genome JJ1886 and clade C/H30 outgroup genome CD306, highlighting differences between
the K14 and K5 capsular region. Blue shading indicates nucleotide identity between sequences
according to BLASTn (95 to 100%). Key genomic regions are indicated: IS: red (185bp
fragment from IS110 family), conserved capsular regions I and III: pink, differing capsular
regions (region II): orange and yellow, other CDSs: black. Image created using Easyfig(57).

439 Among GB-WLS.C2/H30Rx, there is a sub-cluster of 18 isolates from North Wales that are separated by a maximum pair-wise distance of 30 (median: 11, IQR: 8 to 13) non-440 recombinogenic SNPs, highlighting a small, local ST131 cluster. Isolates within this GB-441 WLS.C2/H30Rx sub-cluster from North Wales are distinguishable by 10 unique SNPs and a 442 443 single 1-bp deletion relative to EC958 (Table 2). Additionally, a single strain BA909 (collected in 2014), contained a SNP putatively conferring resistance to rifampicin in rpoB (Q513L)(58). 444 Due to anonymisation of epidemiological data, it is unclear whether isolates BA434 and 445 BA1512 (separated by 9 SNPs, collected 257 days apart) and BA810 and BA909 (separated by 446 12 SNPs, collected 90 days apart) were sampled from the same patient. This analysis however, 447 identified two samples, BA43 and BA910 separated by a single SNP, from two different 448 patients (both male, aged 87 and 77-years) from two different hospitals, 239 days apart. This 449 sequence similarity may suggest that these cases are linked by transmission or were 450 colonised/infected from the same source. Additionally, our data suggests transmission within 451 a single hospital in this same North Wales sub-cluster For example, isolates BA408 and BA434 452

453 from two individual patients collected two days apart from within the same hospital are

<sup>455</sup> 

Table 2. Variants separating Escherichia coli strain EC958 and the North Wales sub-cluster											
Position	56050		<b>C</b> hannah		<b>C</b> a da a	<b>6</b>	Provide the				
In EC958	EC958	Cluster	Change	Impact	Codon	Gene	Product				
900,998	G	A	W=>stop	HIGH	159	nfsA	Oxygen-insensitive NADPH nitroreductase				
1,052,210	G	Т	G=>C	MODERATE	403	ycaQ	Uncharacterized protein				
1,113,811	С	Т	Syn	LOW	74	appB	Cytochrome bd-II ubiquinol oxidase subunit 2				
1,842,716	т	С	S=>P	MODERATE	2	ydiS	Probable electron transfer flavoprotein-quinone oxidoreductase				
2,372,060	G	A	Syn	LOW	413	gatZ	D-tagatose-1,6-bisphosphate aldolase subunit				
2,405,414	CG	С	Deletion	MODIFIER							
2,468,793	G	A	Syn	LOW	92	yeiR	Zinc-binding GTPase				
2,485,972	Α	G	Syn	LOW	302	yejM	Inner membrane protein				
3,196,673	G	A	Syn	LOW	258	xanQ	Xanthine permease				
4,706,103	С	G	W=>S	MODERATE	31	mdtN	Multidrug resistance protein				
4,734,158	Α	G	S=>P	MODERATE	205	basS	Sensor protein				

Emboldened and italicised nucleotides are specific to sub-clade C2/H30Rx EC958 and isolates within the North Wales sub-cluster, respectively <sup>b</sup> Consequence of SNP relative to EC958 (C2/H30Rx). Synonymous change (Syn); non-synonymous changes to protein-coding genes are shown by single letter amino acid abbreviation (EC958 sequence on left, SNP impact on right); blank lines indicate variant in intergenic region

#### 456

# 457 7.5 The root-to-tip distance is consistent with the BEAST2 temporal signal and 458 phylogenetic reconstruction

The divergence time and evolutionary distance for the 215 clade C/H30 ST131 genomes 459 (four strains were removed as they did not match the evolutionary trajectory of the remaining 460 strains) showed a linear relationship (correlation coefficient=0.59), with the regression analysis 461 in TempEST indicating that the genomes accumulate mutations at a rate of  $7.61 \times 10^{-4}$ 462 substitutions per site per year ( $R^2=0.35$ ) (Figure S6). The time to the most recent common 463 ancestor (MRCA) is estimated at the end of 1993 (95% confidence interval: 1989 to 1996). 464 Likewise, BEAST2 pinpoints the time to MRCA to 1994 [95% highest posterior density 465 (HPD): 1986 to 1998] (Figure 3) (based on median node height) and estimates a mutation 466 rate of  $6.87 \times 10^{-4}$  substitutions per site per year (95% HPD:  $5.10 \times 10^{-4}$  to  $8.60 \times 10^{-4}$ ). This 467 translates to 2.85 fixated SNPs per year per genome (95% HPD: 2.12 to 3.57), which means 468 that approximately six SNPs can be expected to differ between two isolates sharing a MRCA 469 one year back in time. A previous study highlighted the within-host diversity of ST131 residing 470 in the intestinal tract of a single patient(17); where strains U13A and U14A were collected nine 471 472 months apart. Here, these strains are depicted to be separated by seven SNPs. This analysis 473 indicates that the CA to U13A and U14A existed approximately two (95% HPD: one to five) 474 years prior to the initial collection of U13A in 2013, which gives credibility to our phylogenetic 475 reconstruction. To correct for ascertainment bias, our dataset describes one SNP for every 963.9 bases across the ~4 Mb core-genome. This translates to a genome-wide mutation rate of 476 7.15×10<sup>-7</sup> mutations/year/site relative to genome size, which is consistent with previous large-477

<sup>454</sup> separated by only two SNPs, suggestive of an epidemiological link.

478 scale temporal analyses of *E. coli*  $[4.39 \times 10^{-7}(10)$  and  $4.14 \times 10^{-7}(59)]$  and *Shigella*  $[6.0 \times 10^{-7}(10)]$ 

479  $^{7}(60)$ ].

480



Figure 3. Evolutionary reconstruction of clade C/H30 Escherichia coli sequence type
(ST)131. A time-calibrated maximum clade credibility tree inferred from 4,150 nonrecombinant orthologous biallelic core-genome single-nucleotide polymorphisms (SNPs).
Moderate recombination SNP density filtering in SPANDx (excluded regions with ≥3 SNPs in
a 100 bp window). SNPs are derived from read mapping to the reference chromosome EC958
(GenBank: HG941718). X-axis represents the emergence time estimates. Isolates from Wales
are shown with reddish purple or orange branches.

489

481

# 490 8. Discussion

491 Recent investigations across England have shown the value of identifying clonal lineages 492 using high-resolution analyses obtainable through WGS for surveillance efforts(4, 7). For 493 example, ECB in England is shown to represent a spill-over from strains circulating in the 494 wider human population(4). This genomic epidemiology study provides a snapshot of the 495 population structure of *E. coli* ST131 associated with bacteraemia in Wales. A final total of

496 142 *E. coli* ST131 strains collected across Wales underwent WGS and were contextualised for
497 their genetic relationship with global ST131 strains through available datasets. To the
498 knowledge of the study authors, this represents the first characterisation of the epidemiological
499 and spatiotemporal nature of ST131 circulating in Wales.

500

501 This study used genomic epidemiology to identify clusters of strains, possibly suggesting patients were colonised/infected from the same source, and demonstrates the benefits of 502 incorporating WGS, stringent quality control and epidemiological data for public health 503 504 surveillance and investigations. Initial phylogenetic relationships were first inferred from SNPs 505 to depict an overall tree topology that represent core-genome alignments of draft genome assemblies. These initial analyses found that, while all three major clades well-supported by 506 507 the literature are represented in ST131 strains circulating in Wales, the predominant lineage is 508 defined by a high prevalence of chromosomal mutations conferring resistance to 509 fluoroquinolones and the presence of AMR genes encoding ESBLs (clade C/H30, particularly sub-clade C2/H30Rx). Subsequent analyses were undertaken to compile a much higher 510 511 resolution of inter-strain relationships by exploiting read mapping of short-read sequence data 512 to a chromosome previously sequenced. These analyses offer the opportunity for the re-513 evaluation of the ST131 clade C/H30 evolutionary trajectory previously characterised(4, 10, 59, 61) and confirms the requirement for careful re-analysis of publicly available genomic data, 514 515 with stringent quality control requirements. The study results highlight the emergence and dissemination of a distinct C2/H30Rx sub-cluster because of an introduction into Wales circa 516 517 1999 (sub-clade C2/H30Rx; 95% HPD: 1996 to 2001), which has been named GB-WLS.C2/H30Rx. The limited genomic diversity (median pair-wise distance of 11 SNPs) 518 519 amongst a distinct GB-WLS.C2/H30Rx sub-cluster from North Wales (which emerged in 2009) suggests that the actual reservoir of infection reservoir was not confined to a single 520 521 nosocomial setting. Analyses into local clusters and transmissions can be highly discriminatory 522 and could become a routine part of surveillance programs with the generation of highly 523 accurate short-reads, and high throughput, from Illumina's short-read sequencing technologies. 524

525 Of particular concern is the high rates of ESBL carriage (66.7%) in ST131 bacteraemia isolates 526 in Wales (clade C/H30), particularly those conferring resistance to 3GCs, from the  $bla_{CTX-M-1}$ 527 (*n*=65/102, 63.7%). These rates are lower than studies in other jurisdictions; 95% of

528 cephalosporin-resistant ST131 isolates in Australia, New Zealand and Singapore showed

isolate carriage of *bla*<sub>CTX-M-15</sub> or *bla*<sub>CTX-M-27</sub>(6) and 82.2% of cefotaxime-resistant UPEC 529 530 isolates from South-West England carried *bla*<sub>CTX-M</sub> variants(62). However, these study 531 methodologies differed by specifically selecting 3GC-resistant isolates for inclusion, whereas 532 this study is population-based and not biased by AMR selection. The rapid global emergence 533 and sustained dominance of clade C/H30 ST131 and the characterisation of the unique ST131 534 Welsh sub-lineage (GB-WLS.C2/H30Rx) highlights the requirement for timely and continuous yearly genomic surveillance, which could facilitate rapid and targeted interventions, for a 535 successful infection control, antimicrobial stewardship, and public health responses. The 536 537 Office for National Statistics has previously collated mortality data where E. coli septicaemia 538 or sepsis were explicitly mentioned on death certificates in Wales between 2001 and 2015(1). 539 Taken together, this collated mortality data combined with genomic surveillance can support 540 the National Health Service (NHS) in Wales by providing timely data for action on serious 541 infections from both healthcare- and community-associated origins with little delay.

542

This study estimates the emergence of fluoroquinolone-resistant C/H30 ST131 circa 1995 543 544 (95% HPD: 1991 to 1998). This differs from the previously reported dates from Ben Zakour et al.(10), Stoesser et al.(61), and Kallonen et al.(4), that estimate 1987 (95% HPD: 1983 to 545 546 1992), 1982 (95% HPD: 1948 to 1995), and circa 1987, respectively. In contrast, after analysing 794 ST131 genomes, Ludden et al.(59) supports our findings and pinpoints the 547 548 emergence of the fluoroquinolone-resistant C/H30 ancestor to 1992 (95% HPD 1989 to 1994). While the posterior mean/median node heights for the clades vary between studies, it is 549 550 important to recognise that the 95% HPD intervals overlap. The variation in study results is likely due to the enhanced methodology utilised, including: stringent quality control metrics, 551 552 improved versions of tools and methods, use of a high quality clade C reference genome, the exclusion of clade B ST131 strains, and the inclusion of a fluoroquinolone sensitive clade 553 554 C/H30 outgroup strain (CD306).

555

These highly discriminatory analyses reveal multiple introductions of sub-clade C2/H30Rx into Wales before an emergence circa 1999 (95% HPD: 1996 to 2001) of the unique clonal sub-lineage (GB-WLS.C2/H30Rx), which shares a CA of North American origin. These unique strains (GB-WLS.C2/H30Rx) were related with a median pair-wise SNP distance of 48 non-recombinogenic SNPs, which could indicate localised transmission with an unidentified infection reservoir. The CA to this unique strain (GB-WLS.C2/H30Rx) is distinguishable from

that shared with the basal S125EC strain by an impairment of ferric enterobactin synthesis and 562 transport due to a premature termination because of a Q130stop codon in *fepE*, and the loss of 563 564 a region encompassing the capsular biosynthesis genes for a K5 capsular antigen. Notably, both 565 enterobactin and the capsule are known UPEC virulence factors. Whether the inactivation of 566 these genes resulted in a decrease in virulence remains to be elucidated and represents a 567 research question for future investigation. For strains within GB-WLS.C2/H30Rx, region II of 568 the capsular loci was replaced with a chloramphenicol acetyltransferase (CAT) and HAD-IA family hydrolase. CATs inactivate chloramphenicol by generating derivatives like 1-acetoxy 569 570 chloramphenicol, 3-acetoxy chloramphenicol, or 1,3-diacetoxy chloramphenicol. These 571 derivatives are unable to inhibit bacterial growth and survival as interruption of the ribosomal 572 peptidyl-transferase is no longer possible(63, 64). Further, the identification of a local cluster 573 within North Wales, MRCA emerged in 2009, with very closely related strains differing by a 574 median of 11 non-recombinant pair-wise SNPs, suggests that there was possible direct 575 transmission between these individuals. Although, the anonymisation of patient data limits confirmation of an actual nosocomial infection reservoir and evidence of negative (or positive) 576 577 culture on admission would be required for any certainty.

578

579 The study design describes cases of bacteraemia, with confirmed blood cultures, caused by 580 ST131 in Wales. This is likely a consequence of UTI treatment failure due to AMR, although further research is needed to establish links between confirmed blood and urine isolates. 581 582 Therefore, this study may not represent the whole population structure of GB-WLS.C2/H30Rx in UTIs in Wales. In this circumstance, one would expect increased rates of AMR, and thus it 583 584 is likely that the population structure of all GB-WLS.C2/H30Rx is to be less resistant than might be expected based upon the results reported here. Globally there is a necessity to acquire 585 586 a deeper understanding of the population structure of UPEC, so that UPEC strains that are more 587 likely to result in treatment failure and progress to bacteraemia can be identified as a risk factor. 588 This can be achieved through the identification and tracking of genomic sequences (e.g. AMR 589 determinants and virulence factors) as indicators for predicting phenotypic characteristics. One 590 of the key strengths of our study was our ability to avoid a temporal or geographical bias in our 591 dataset by contextualising the ST131 Welsh strains with global isolates. This lack of bias was reflected by our population expansion timeline which coincides with the initial detection of 592 ST131 in the UK in 2003(4), before becoming the predominant clone (n=52/88, 59.1%) in the 593 594 Northwest of England between 2004 and 2006(7). Previous studies of whole-genome SNP

discovery for phylogenetics(6, 9, 10) have used the Bowtie 2(37, 65) or the SHRiMP(66) read 595 596 aligner with FreeBayes(67) within the Nesoni pipeline (https://github.com/Victorian-Bioinformatics-Consortium/nesoni). However, SPANDx was utilised for the methodology 597 598 employed in this study as it has been peer reviewed(46) and is under regular development, with v4.0.1 released on 02 April 2020. Additionally, previous quality assurance analyses using 599 600 SPANDx have been reported(68) to ensure; a single mixed strain does not affect tree topology 601 and phylogenetic inference, and the importance of assessing datasets for the presence of mixed 602 strains prior to phylogenetic analyses.

603

#### 604 8.1 Conclusion

Genomic epidemiological analyses on 142 ST131 strains associated with bacteraemia 605 across Wales between 2013 and 2014 were performed using whole-genome sequencing. This 606 607 research demonstrates the requirement to reanalyse publicly available genomic data, with stringent quality control, to improve the evolutionary trajectory of the ST131 clade C/H30 608 previously characterised. This study showed geographical clustering of sub-clade C2/H30Rx 609 in North Wales; characterised by genotypic resistance to third-generation cephalosporins, 610 fluoroquinolones, chloramphenicol, and nitrofurantoin. This emergence follows the 611 introduction of a single sub-lineage into Wales circa 1999 and its expansion and persistence, 612 613 which the authors have named GB-WLS.C2/H30Rx. This study highlights the need to incorporate whole-genome sequencing with epidemiological data and a 'One Health' approach 614 615 to identify potential infection reservoirs in the environment, which will allow for the identification of ST131 transmission dynamics between healthcare settings and the community. 616 617 This study displays a novel localised cluster of ST131 bacteraemia in Wales captured between 2013 and 2014. By gaining a detailed understanding of significant E. coli bacteraemia strains, 618 619 it should be possible to develop targeted public health measures to reduce the risk of E. coli 620 bacteraemia and act to combat the rise of antimicrobial resistance.

621

# 622 9. Data Bibliography

- 623 1. White R.T. *et al.* BioProject PRJNA729115 (2021).
- 624 2. Kidsley A. K. *et al.* BioProject PRJNA627752 (2020).
- 625 3. Johnson, T. J. *et al.* BioProject PRJNA307507 (2016).
- 626 4. Johnson, T. J. *et al.* BioProject PRJNA311313 (2016).

- 627 5. Petty, N. K. *et al.* BioProject PRJEB2968 (2014).
- 628 6. Price, L. B. et al. BioProject PRJNA211153 (2013).
- 629 7. Andersen, P. S. et al. BioProject PRJNA218163 (2013).
- 630 8. Totsika, M. *et al.* BioProject PRJEA61443 (2011).
- 631 9. Toh H. *et al.*, BioProject PRJDA19053 (2010).
- 632

#### 633 **10. Author statements**

#### 634 10.1 Authors and contributors

Conceptualisation: R.T.W. Investigation: R.T.W. Funding was acquired by T.R.C. and 635 computational resources were supported by S.A.B. Formal analysis: R.T.W. Wet-lab 636 experiments: M.J.B. and C.R.B. Data analysis: R.T.W. Data curation: central Specialist 637 Antimicrobial Chemotherapy Unit (SACU) at Public Health Wales, University Hospital Wales, 638 T.R.C., and R.T.W. Illumina sequencing was done at the Oxford Genomics Centre and 639 MicrobesNG at the University of Birmingham. Supervision: T.R.C., B.M.F., and S.A.B. 640 641 Writing (Original Draft Preparation): R.T.W. Writing (Review and Editing): R.T.W., M.J.B., C.R.B., J.M.A., M.W., L.S.J., R.A.H., M.M., M.M.A., B.M.F., T.R.C., and S.A.B. All authors 642 have read and approved the final version of the manuscript. 643

644

#### 645 10.2 Conflicts of interest

- 646 The authors declare that there are no conflicts of interest.
- 647

#### 648 10.3 Funding information

649 This work received funding for whole-genome sequencing from Public Health Wales NHS
650 Trust (United Kingdom) and a Wellcome Institutional Strategic Support Fund (ISSF) award to
651 Cardiff University (United Kingdom).

652

#### 653 **10.4 Ethical approval**

This work was undertaken on stored bacterial cultures and no additional clinical samples were collected from any persons to facilitate this study. Patient anonymity was maintained by pseudonymised data that went outside Public Health Wales.

#### 658 10.5 Acknowledgements

We thank the Public Health Wales laboratories and the Specialist Antimicrobial 659 660 Chemotherapy Unit at University Hospital Wales for their contributions from the national 661 public health surveillance of bacteraemia cases in Wales. We acknowledge the facilities, and 662 the scientific and technical assistance of staff at the Oxford Genomics Centre and MicrobesNG 663 at the University of Birmingham. This research was supported by ORIScloud and by use of the 664 Nectar Research Cloud. The Nectar Research Cloud is a collaborative Australian research platform supported by the National Collaborative Research Infrastructure Strategy (NCRIS). 665 666 Sequence data are uploaded and stored on the centralised Cloud Infrastructure for Microbial Bioinformatics (MRC-CLIMB) server, which is funded by the Medical Research Council 667 (MRC) (grant codes MR/L015080/1 and MR/T030062/1). The author would like to thank 668 Derek Sarovich and Erin Price (GeneCology Research Centre at the University of the Sunshine 669 Coast, and the Sunshine Coast Health Institute) and Thomas Cuddihy (QFAB Bioinformatics 670 and Research Computing Centre, The University of Queensland) for high-performance 671 computing support and helpful discussions about software functionality. 672

673

# 674 **11. References**

- 675
  1. Office for National Statistics. Deaths involving E. coli septicaemia, deaths registered in Wales between
  676 2001 and 2015. London, United Kingdom: Office for National Statistics; 2016. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/adhocs/006005de
  678 athsinvolvingecolisepticaemiadeathsregisteredinwalesbetween2001and2015 [Accessed 05 May 2021]
- 679 2. Wozniak TM, Bailey EJ, Graves N. Health and economic burden of antimicrobial-resistant infections in Australian hospitals: a population-based model. *Infection Control & Hospital Epidemiology* 2019;40:320-327 doi: 10.1017/ice.2019.2
- 682 3. Riley LW. Pandemic lineages of extraintestinal pathogenic *Escherichia coli*. *Clinical Microbiology and Infection* 2014;20:380-390 doi: 10.1111/1469-0691.12646
- 4. Kallonen T, Brodrick HJ, Harris SR, Corander J, Brown NM, Martin V, *et al.* Systematic longitudinal survey of invasive *Escherichia coli* in England demonstrates a stable population structure only transiently disturbed by the emergence of ST131. *Genome Research* 2017;27:1437-1449 doi: 10.1101/gr.216606.116
- 5. Day MJ, Doumith M, Abernethy J, Hope R, Reynolds R, Wain J, et al. Population structure of *Escherichia* coli causing bacteraemia in the UK and Ireland between 2001 and 2010. *Journal of Antimicrobial* Chemotherapy 2016;71:2139-2142 doi: 10.1093/jac/dkw145
- 6. Harris PNA, Ben Zakour NL, Roberts LW, Wailan AM, Zowawi HM, Tambyah PA, *et al.* Whole genome analysis of cephalosporin-resistant *Escherichia coli* from bloodstream infections in Australia, New Zealand and Singapore: high prevalence of CMY-2 producers and ST131 carrying *bla*<sub>CTX-M-15</sub> and *bla*<sub>CTX-M-5</sub>
  693 27. *Journal of Antimicrobial Chemotherapy* 2018;73:634-642 doi: 10.1093/jac/dkx466
- Lau SH, Reddy S, Cheesbrough J, Bolton FJ, Willshaw G, Cheasty T, *et al.* Major uropathogenic
   *Escherichia coli* strain isolated in the northwest of England identified by multilocus sequence typing. Journal
   of Clinical Microbiology 2008;46:1076-1080 doi: 10.1128/JCM.02065-07
- 8. Johnson JR, Johnston B, Clabots C, Kuskowski MA, Castanheira M. Escherichia coli sequence type
  ST131 as the major cause of serious multidrug-resistant *E. coli* infections in the United States. *Clinical Infectious Diseases* 2010;51:286-294 doi: 10.1086/653932

- Petty NK, Ben Zakour NL, Stanton-Cook M, Skippington E, Totsika M, Forde BM, et al. Global dissemination of a multidrug resistant *Escherichia coli* clone. *Proceedings of the National Academy of Sciences of the United States of America* 2014;111:5694-5699 doi: 10.1073/pnas.1322678111
- Ben Zakour NL, Alsheikh-Hussain AS, Ashcroft MM, Khanh Nhu NT, Roberts LW, Stanton-Cook M,
   *et al.* Sequential acquisition of virulence and fluoroquinolone resistance has shaped the evolution of *Escherichia coli* ST131. *mBio* 2016;7:e00347-16 doi: 10.1128/mBio.00347-16
- Totsika M, Beatson SA, Sarkar S, Phan MD, Petty NK, Bachmann N, *et al.* Insights into a multidrug
   resistant *Escherichia coli* pathogen of the globally disseminated ST131 lineage: genome analysis and
   virulence mechanisms. *PLOS ONE* 2011;6 doi: 10.1371/journal.pone.0026578
- 709 12. Gibreel TM, Dodgson AR, Cheesbrough J, Bolton FJ, Fox AJ, Upton M. High metabolic potential may
   710 contribute to the success of ST131 uropathogenic *Escherichia coli*. *Journal of Clinical Microbiology* 711 2012;50:3202-3207 doi: 10.1128/JCM.01423-12
- Totsika M, Kostakioti M, Hannan TJ, Upton M, Beatson SA, Janetka JW, *et al.* A FimH inhibitor
   prevents acute bladder infection and treats chronic cystitis caused by multidrug-resistant uropathogenic
   *Escherichia coli* ST131. *The Journal of Infectious Diseases* 2013;208:921-928 doi: 10.1093/infdis/jit245
- Phan MD, Peters KM, Sarkar S, Lukowski SW, Allsopp LP, Gomes Moriel D, et al. The serum resistome of a globally disseminated multidrug resistant uropathogenic *Escherichia coli* clone. *PLOS Genetics* 2013;9:e1003834 doi: 10.1371/journal.pgen.1003834
- 718 15. Goh KGK, Phan MD, Forde BM, Chong TM, Yin WF, Chan KG, et al. Genome-wide discovery of genes required for capsule production by uropathogenic *Escherichia coli*. mBio 2017;8 doi: 10.1128/mbio.01558-17
- Mathers AJ, Peirano G, Pitout JD. The role of epidemic resistance plasmids and international high-risk
   clones in the spread of multidrug-resistant Enterobacteriaceae. *Clinical Microbiology Reviews* 2015;28:565 591 doi: 10.1128/cmr.00116-14
- Forde BM, Roberts LW, Phan MD, Peters KM, Fleming BA, Russell CW, *et al.* Population dynamics of
   an *Escherichia coli* ST131 lineage during recurrent urinary tract infection. *Nature Communications* 2019;10:3643 doi: 10.1038/s41467-019-11571-5
- 18. Coque TM, Novais A, Carattoli A, Poirel L, Pitout J, Peixe L, *et al.* Dissemination of clonally related
   *Escherichia coli* strains expressing extended-spectrum beta-lactamase CTX-M-15. *Emerging Infectious Diseases* 2008;14:195-200 doi: 10.3201/eid1402.070350
- Peirano G, Pitout JD. Molecular epidemiology of *Escherichia coli* producing CTX-M beta-lactamases: the
   worldwide emergence of clone ST131 O25:H4. *International Journal of Antimicrobial Agents* 2010;35:316-321 doi: 10.1016/j.ijantimicag.2009.11.003
- Johnson JR, Johnston B, Clabots C, Kuskowski MA, Pendyala S, Debroy C, *et al.* Escherichia coli
   sequence type ST131 as an emerging fluoroquinolone-resistant uropathogen among renal transplant
   recipients. Antimicrobial Agents and Chemotherapy 2010;54:546-550 doi: 10.1128/AAC.01089-09
- 736 21. National Institute for Clinical Excellence. *Pyelonephritis (acute): antimicrobial prescribing*. London,
   737 United Kingdom: Public Health England; 2018. Available from: https://www.nice.org.uk/guidance/ng111
   738 [Accessed 19 May 2021]
- 22. Livermore DM, Canton R, Gniadkowski M, Nordmann P, Rossolini GM, Arlet G, et al. CTX-M:
  changing the face of ESBLs in Europe. Journal of Antimicrobial Chemotherapy 2007;59:165-174 doi: 10.1093/jac/dkl483
- 742 23. Public Health England. English surveillance programme for antimicrobial utilisation and resistance
  743 (ESPAUR) report. London, United Kingdom; 2019. Available from: 144 https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\_data/file/936199/E
  745 SPAUR Report\_2019-20.pdf [Accessed 19 May 2021]
- 746 24. Heginbothom M, Howe R, Davies E. Antibacterial resistance in Wales 2008-2017. Cardiff, United
  747 Kingdom: Public Health Wales; 2018. Available from: http://www.wales.nhs.uk/sitesplus/documents/888/Antimicrobial%20Resistance%20in%20Wales%202008-2017%20v1.pdf [Accessed 19 May 2021]
- Peirano G, Schreckenberger PC, Pitout JD. Characteristics of NDM-1-producing *Escherichia coli* isolates
   that belong to the successful and virulent clone ST131. *Antimicrobial Agents and Chemotherapy* 2011;55:2986-2988 doi: 10.1128/AAC.01763-10

- 753 26. Morris D, McGarry E, Cotter M, Passet V, Lynch M, Ludden C, *et al.* Detection of OXA-48
  754 carbapenemase in the pandemic clone *Escherichia coli* O25b:H4-ST131 in the course of investigation of an outbreak of OXA-48-producing *Klebsiella pneumoniae*. *Antimicrobial Agents and Chemotherapy* 2012;56:4030-4031 doi: 10.1128/AAC.00638-12
- 757 27. National Institute for Clinical Excellence. Urinary tract infection (lower): antimicrobial prescribing.
   758 London, United Kingdom: Public Health England; 2018. Available from: https://www.nice.org.uk/guidance/ng109 [Accessed 19 May 2021]
- Zerbino DR, Birney E. Velvet: algorithms for *de novo* short read assembly using de Bruijn graphs. *Genome Research* 2008;18:821-829 doi: 10.1101/gr.074492.107
- 762 29. Boetzer M, Pirovano W. Toward almost closed genomes with GapFiller. *Genome Biology* 2012;13:R56 doi: 10.1186/gb-2012-13-6-r56
- 30. Assefa S, Keane TM, Otto TD, Newbold C, Berriman M. ABACAS: algorithm-based automatic contiguation of assembled sequences. *Bioinformatics* 2009;25:1968-1969 doi: 10.1093/bioinformatics/btp347
- Tsai IJ, Otto TD, Berriman M. Improving draft assemblies by iterative mapping and assembly of short reads to eliminate gaps. *Genome Biology* 2010;11:R41 doi: 10.1186/gb-2010-11-4-r41
- 32. Boetzer M, Henkel CV, Jansen HJ, Butler D, Pirovano W. Scaffolding pre-assembled contigs using
   SSPACE. *Bioinformatics* 2011;27:578-579 doi: 10.1093/bioinformatics/btq683
- Walker BJ, Abeel T, Shea T, Priest M, Abouelliel A, Sakthikumar S, *et al.* Pilon: an integrated tool for
   comprehensive microbial variant detection and genome assembly improvement. *PLOS ONE* 2014;9:e112963
   10.1371/journal.pone.0112963
- 34. Chevreux B, Pfisterer T, Drescher B, Driesel AJ, Muller WE, Wetter T, *et al.* Using the miraEST assembler for reliable and automated mRNA transcript assembly and SNP detection in sequenced ESTs. *Genome Research* 2004;14:1147-1159 doi: 10.1101/gr.1917404
- 35. Darling AC, Mau B, Blattner FR, Perna NT. Mauve: multiple alignment of conserved genomic sequence
   with rearrangements. *Genome Research* 2004;14:1394-1403 doi: 10.1101/gr.2289704
- 36. Gurevich A, Saveliev V, Vyahhi N, Tesler G. QUAST: quality assessment tool for genome assemblies.
   *Bioinformatics* 2013;29:1072-1075 doi: 10.1093/bioinformatics/btt086
- 780 37. Kidsley AK, White RT, Beatson SA, Saputra S, Schembri MA, Gordon D, *et al.* Companion animals are
  781 spillover hosts of the multidrug-resistant human extraintestinal *Escherichia coli* pandemic clones ST131 and
  782 ST1193. *Frontiers in Microbiology* 2020;11:1968 doi: 10.3389/fmicb.2020.01968
- 783 38. Price LB, Johnson JR, Aziz M, Clabots C, Johnston B, Tchesnokova V, *et al.* The epidemic of extended 784 spectrum-beta-lactamase-producing *Escherichia coli* ST131 is driven by a single highly pathogenic subclone,
   785 H30-Rx. *mBio* 2013;4:e00377-13 doi: 10.1128/mBio.00377-13
- 39. Huang W, Li L, Myers JR, Marth GT. ART: a next-generation sequencing read simulator. *Bioinformatics* 2012;28:593-594 doi: 10.1093/bioinformatics/btr708
- 40. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* 2009;25:1754-1760 doi: 10.1093/bioinformatics/btp324
- 41. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, *et al.* The Sequence Alignment/Map format and SAMtools. *Bioinformatics* 2009;25:2078-2079 doi: 10.1093/bioinformatics/btp352
- McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, *et al.* The Genome Analysis
   Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Research* 2010;20:1297-1303 doi: 10.1101/gr.107524.110
- 795 43. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, *et al.* A framework for variation discovery and genotyping using next-generation DNA sequencing data. *Nature Genetics* 2011;43:491-498 doi: 10.1038/ng.806
- 44. Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. *Bioinformatics* 2010;26:841-842 doi: 10.1093/bioinformatics/btq033
- 45. Cingolani P, Platts A, Wang le L, Coon M, Nguyen T, Wang L, *et al.* A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of *Drosophila melanogaster* strain w<sup>1118</sup>; iso-2; iso-3. *Fly* 2012;6:80-92 doi: 10.4161/fly.19695
- 803
   46. Sarovich DS, Price EP. SPANDx: a genomics pipeline for comparative analysis of large haploid whole genome re-sequencing datasets. *BMC Research Notes* 2014;7:618 doi: 10.1186/1756-0500-7-618

- 805
   47. Stamatakis A. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies.
   806 *Bioinformatics* 2014;30:1312-1313 doi: 10.1093/bioinformatics/btu033
- 48. Zhang H, Gao S, Lercher MJ, Hu S, Chen WH. EvolView, an online tool for visualizing, annotating and managing phylogenetic trees. *Nucleic Acids Research* 2012;40:W569-W572 doi: 10.1093/nar/gks576
- 49. He Z, Zhang H, Gao S, Lercher MJ, Chen WH, Hu S. Evolview v2: an online visualization and management tool for customized and annotated phylogenetic trees. *Nucleic Acids Research* 2016;44:W236-W241 doi: 10.1093/nar/gkw370
- 812 50. Rambaut A, Lam TT, Max Carvalho L, Pybus OG. Exploring the temporal structure of heterochronous
   813 sequences using TempEst (formerly Path-O-Gen). *Virus Evolution* 2016;2:vew007 doi: 10.1093/ve/vew007
- 814 51. Bouckaert R, Heled J, Kuhnert D, Vaughan T, Wu CH, Xie D, et al. BEAST 2: a software platform for
   815 Bayesian evolutionary analysis. *PLOS Computational Biology* 2014;10:e1003537 doi:
   816 /10.1371/journal.pcbi.1003537
- 52. Darriba D, Taboada GL, Doallo R, Posada D. jModelTest 2: more models, new heuristics and parallel computing. *Nature Methods* 2012;9:772 doi: 10.1038/nmeth.2109
- S3. Guindon S, Gascuel O. A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. *Systematic Biology* 2003;52:696-704 doi: 10.1080/10635150390235520
- 821 54. Arnott JM, Morgan M. *Escherichia coli* bacteraemia in Wales, a case-series analysis. Poster presented at:
   822 Public Health England's Applied Epidemiology Scientific Conference. Coventry, United Kingdom; 2016.
- 823 55. Whitfield C. Biosynthesis and assembly of capsular polysaccharides in *Escherichia coli*. Annual Review of
   824 *Biochemistry* 2006;75:39-68 doi: 10.1146/annurev.biochem.75.103004.142545
- 825 56. Whitfield C, Roberts IS. Structure, assembly and regulation of expression of capsules in *Escherichia coli*.
   826 Molecular Microbiology 1999;31:1307-1319 doi: 10.1046/j.1365-2958.1999.01276.x
- 57. Sullivan MJ, Petty NK, Beatson SA. Easyfig: a genome comparison visualizer. *Bioinformatics* 2011;27:1009-1010 doi: 10.1093/bioinformatics/btr039
- 58. Jin DJ, Gross CA. Mapping and sequencing of mutations in the *Escherichia coli rpoB* gene that lead to rifampicin resistance. *Journal of Molecular Biology* 1988;202:45-58 doi: 10.1016/0022-2836(88)90517-7
- 59. Ludden C, Decano AG, Jamrozy D, Pickard D, Morris D, Parkhill J, et al. Genomic surveillance of *Escherichia coli* ST131 identifies local expansion and serial replacement of subclones. *Microbial Genomics* 2020;6 doi: 10.1099/mgen.0.000352
- 834 60. Holt KE, Thieu Nga TV, Thanh DP, Vinh H, Kim DW, Vu Tra MP, et al. Tracking the establishment of
  835 local endemic populations of an emergent enteric pathogen. Proceedings of the National Academy of Sciences
  836 of the United States of America 2013;110:17522-17527 doi: 10.1073/pnas.1308632110
- 837 61. Stoesser N, Sheppard AE, Pankhurst L, De Maio N, Moore CE, Sebra R, et al. Evolutionary history of
  838 the global emergence of the *Escherichia coli* epidemic clone ST131. mBio 2016;7:e02162 doi:
  839 10.1128/mBio.02162-15
- Findlay J, Gould VC, North P, Bowker KE, Williams MO, MacGowan AP, et al. Characterization of cefotaxime-resistant urinary *Escherichia coli* from primary care in South-West England 2017-18. *Journal of Antimicrobial Chemotherapy* 2020;75:65-71 doi: 10.1093/jac/dkz397
- 63. Cammarata A. The molecular basis of antibiotic action. By Gale EF, Cundliffe E, Reynolds PE, Richmond
  MH, and Waring MJ. New York, United States of America: Wiley; 1972 doi: 10.1002/jps.2600620955
- 845
   64. Pongs O. Chloramphenicol. In: Hahn FE, editor. Antibiotics V Mechanism of Action of Antibacterial
   846 Agents. New York, United States of America: Springer-Verlag; 1979. pp. 272–303.
- 847 65. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. *Nature Methods* 2012;9:357-359
   848 doi: 10.1038/nmeth.1923
- 849 66. Rumble SM, Lacroute P, Dalca AV, Fiume M, Sidow A, Brudno M. SHRiMP: accurate mapping of short color-space reads. *PLOS Computational Biology* 2009;5:e1000386 doi: 10.1371/journal.pcbi.1000386
- 67. Garrison E, Marth G. Haplotype-based variant detection from short-read sequencing. arXiv:12073907v2
   [Preprint]. 2012. Available from: https://arxiv.org/abs/1207.3907v2
- Aziz A, Currie BJ, Mayo M, Sarovich DS, Price EP. Comparative genomics confirms a rare melioidosis
   human-to-human transmission event and reveals incorrect phylogenomic reconstruction due to polyclonality.
   *Microbial Genomics* 2020;6 doi: 10.1099/mgen.0.000326
- 856